Immunome, Inc.

Revenue is set to grow 209%/yr over the next 3 years, ahead of most of the market.8/10

Revenue held flat over the last 3 years and is set to grow 209%/yr from here.

The runway holds up: revenue is set to grow 143%/yr over five years.10/10

A mid-pack grower, ahead of 63% of companies worldwide.

The company is loss-making, so its revenue growth is not backed by profit yet.

A middle-of-the-pack grower that's speeding up. The one thing to watch: the company is not profitable yet.

Strong long-term results. Long-term holders have seen +148% over three years and +7.8% over five, ahead of 60% of the market.

It's up 36% over the past year, but 36% below its 52-week high. That is a touch ahead of the market.

The stock is underperforming over the past month (-29%), over three months (-20%) and so far this year (-11%).

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the stock is underperforming over the past month, over three months and so far this year.